{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:16:04Z","timestamp":1784031364405,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47999-1","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:06:20Z","timestamp":1775923580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multi-gene urinary extracellular vesicle mRNA panel as a non-invasive biomarkers for prostate cancer detection"],"prefix":"10.1038","volume":"16","author":[{"given":"Sreekanth","family":"Patnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Koppula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarwareddy Kartik","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Thalakanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh V.","family":"Bendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjai","family":"Addla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-5277","authenticated-orcid":false,"given":"Sasidhar Venkata","family":"Manda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"3","key":"47999_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u201363 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"47999_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/pros.24360","volume":"82","author":"D Withrow","year":"2022","unstructured":"Withrow, D. et al. Current and projected number of years of life lost due to prostate cancer: A global study. Prostate 82(11), 1088\u201397 (2022).","journal-title":"Prostate"},{"issue":"8","key":"47999_CR3","first-page":"1","volume":"4","author":"R Bhargavi","year":"2023","unstructured":"Bhargavi, R. et al. Prostate cancer in India: Current perspectives and the way forward. Journal of Reproductive Health and Medicine 4(8), 1\u20138 (2023).","journal-title":"Journal of Reproductive Health and Medicine"},{"issue":"1","key":"47999_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.urolonc.2024.06.003","volume":"43","author":"VM Sundaresan","year":"2025","unstructured":"Sundaresan, V. M. et al. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urol. Oncol. 43(1), 41\u20138 (2025).","journal-title":"Urol. Oncol."},{"key":"47999_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071728","author":"F Ionescu","year":"2022","unstructured":"Ionescu, F., Zhang, J. & Wang, L. Clinical applications of liquid biopsy in prostate cancer: From screening to predictive biomarker. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14071728 (2022).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"47999_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/applbiosci4020024","volume":"4","author":"CG Costi","year":"2025","unstructured":"Costi, C. G. et al. Urinary markers for prostate cancer: State of the art. Applied Biosciences 4(2), 24 (2025).","journal-title":"Applied Biosciences"},{"issue":"3","key":"47999_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/cancers2031432","volume":"2","author":"M Salagierski","year":"2010","unstructured":"Salagierski, M. & Schalken, J. A. PCA3 and TMPRSS2-ERG: Promising biomarkers in prostate cancer diagnosis. Cancers (Basel) 2(3), 1432\u20131440 (2010).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"47999_CR8","doi-asserted-by":"publisher","first-page":"e0285745","DOI":"10.1371\/journal.pone.0285745","volume":"19","author":"H Wu","year":"2024","unstructured":"Wu, H. et al. A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer. PLoS One. 19 (2), e0285745 (2024).","journal-title":"PLoS One"},{"issue":"1","key":"47999_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins, S. A. et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur. Urol. 70(1), 45\u201353 (2016).","journal-title":"Eur. Urol."},{"key":"47999_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010165","author":"T Borbiev","year":"2023","unstructured":"Borbiev, T., Kohaar, I. & Petrovics, G. Clinical biofluid assays for prostate cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16010165 (2023).","journal-title":"Cancers (Basel)"},{"key":"47999_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062118","author":"T Lorenc","year":"2020","unstructured":"Lorenc, T. et al. Exosomes in prostate cancer diagnosis, prognosis and therapy. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21062118 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"47999_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41416-021-01610-8","volume":"126","author":"M Ramirez-Garrastacho","year":"2022","unstructured":"Ramirez-Garrastacho, M. et al. Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research. Br. J. Cancer. 126 (3), 331\u2013350 (2022).","journal-title":"Br. J. Cancer"},{"issue":"4","key":"47999_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/pcan.2015.40","volume":"18","author":"MJ Donovan","year":"2015","unstructured":"Donovan, M. J. et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 18 (4), 370\u2013375 (2015).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"47999_CR14","doi-asserted-by":"publisher","first-page":"e0154507","DOI":"10.1371\/journal.pone.0154507","volume":"11","author":"P Motamedinia","year":"2016","unstructured":"Motamedinia, P. et al. Urine exosomes for non-invasive assessment of gene expression and mutations of prostate cancer. PLoS One 11(5), e0154507 (2016).","journal-title":"PLoS One"},{"issue":"2","key":"47999_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","volume":"25","author":"E Margolis","year":"2022","unstructured":"Margolis, E. et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 25 (2), 296\u2013301 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"47999_CR16","doi-asserted-by":"publisher","first-page":"736110","DOI":"10.3389\/fmed.2022.736110","volume":"9","author":"J Gan","year":"2022","unstructured":"Gan, J. et al. Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes. Front. Med. (Lausanne). 9, 736110 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"7","key":"47999_CR17","doi-asserted-by":"publisher","first-page":"e70047","DOI":"10.1371\/journal.pone.0070047","volume":"8","author":"K Gabriel","year":"2013","unstructured":"Gabriel, K. et al. Regulation of the tumor suppressor PTEN through exosomes: A diagnostic potential for prostate cancer. PLoS One 8(7), e70047 (2013).","journal-title":"PLoS One"},{"issue":"3","key":"47999_CR18","first-page":"2856","volume":"17","author":"X Zhou","year":"2019","unstructured":"Zhou, X. et al. Effect of PTEN loss on metabolic reprogramming in prostate cancer cells. Oncol. Lett. 17(3), 2856\u201366 (2019).","journal-title":"Oncol. Lett."},{"key":"47999_CR19","doi-asserted-by":"publisher","first-page":"904315","DOI":"10.3389\/fonc.2022.904315","volume":"12","author":"X Jin","year":"2022","unstructured":"Jin, X. et al. Urine Exosomal AMACR Is a Novel Biomarker for Prostate Cancer Detection at Initial Biopsy. Front. Oncol. 12, 904315 (2022).","journal-title":"Front. Oncol."},{"issue":"5","key":"47999_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/bju.12120","volume":"111","author":"D Hossain","year":"2013","unstructured":"Hossain, D. & Bostwick, D. G. Significance of the TMPRSS2:ERG gene fusion in prostate cancer. BJU Int. 111(5), 834\u20135 (2013).","journal-title":"BJU Int."},{"issue":"4","key":"47999_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/onc.2015.109","volume":"35","author":"P Adamo","year":"2016","unstructured":"Adamo, P. & Ladomery, M. R. The oncogene ERG: A key factor in prostate cancer. Oncogene 35(4), 403\u201314 (2016).","journal-title":"Oncogene"},{"issue":"6","key":"47999_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/pros.21273","volume":"71","author":"H Bu","year":"2011","unstructured":"Bu, H. et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 71 (6), 575\u2013587 (2011).","journal-title":"Prostate"},{"issue":"5","key":"47999_CR23","first-page":"5107","volume":"18","author":"J Meiners","year":"2019","unstructured":"Meiners, J. et al. Upregulation of SPDEF is associated with poor prognosis in prostate cancer. Oncol. Lett. 18 (5), 5107\u20135118 (2019).","journal-title":"Oncol. Lett."},{"issue":"61","key":"47999_CR24","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.18632\/oncotarget.27284","volume":"10","author":"AEG Lemos","year":"2019","unstructured":"Lemos, A. E. G., Matos, A. D. R., Ferreira, L. B. & Gimba, E. R. P. The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer. Oncotarget 10 (61), 6589\u20136603 (2019).","journal-title":"Oncotarget"},{"key":"47999_CR25","doi-asserted-by":"publisher","first-page":"102310","DOI":"10.1016\/j.mex.2023.102310","volume":"11","author":"AD Singh","year":"2023","unstructured":"Singh, A. D. et al. Polyethylene glycol-based isolation of urinary extracellular vesicles, an easily adoptable protocol. MethodsX 11, 102310 (2023).","journal-title":"MethodsX"},{"issue":"Database issue","key":"47999_CR26","doi-asserted-by":"publisher","first-page":"D792","DOI":"10.1093\/nar\/gkp1005","volume":"38","author":"A Spandidos","year":"2010","unstructured":"Spandidos, A., Wang, X., Wang, H. & Seed, B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 38 (Database issue), D792\u2013D799 (2010).","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"47999_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3(6), 1101\u20138 (2008).","journal-title":"Nat. Protoc."},{"key":"47999_CR28","doi-asserted-by":"publisher","first-page":"1066118","DOI":"10.3389\/fgene.2022.1066118","volume":"13","author":"T Shinawi","year":"2022","unstructured":"Shinawi, T. et al. A comparative mRNA- and miRNA transcriptomics reveals novel molecular signatures associated with metastatic prostate cancers. Front. Genet. 13, 1066118 (2022).","journal-title":"Front. Genet."},{"key":"47999_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-5-45","volume":"5","author":"UR Chandran","year":"2005","unstructured":"Chandran, U. R. et al. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 5, 45 (2005).","journal-title":"BMC Cancer"},{"issue":"2","key":"47999_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/erm.10.122","volume":"11","author":"X Durand","year":"2011","unstructured":"Durand, X., Moutereau, S., Xylinas, E. & de la Taille, A. Progensa\u2122 PCA3 test for prostate cancer. Expert Rev. Mol. Diagn. 11(2), 137\u201344 (2011).","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"6","key":"47999_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.acuro.2020.10.010","volume":"45","author":"D Fiorella","year":"2021","unstructured":"Fiorella, D. et al. Role of PCA3 and SelectMDx in the optimization of active surveillance in prostate cancer. Actas Urol. Esp. (Engl Ed). 45 (6), 439\u2013446 (2021).","journal-title":"Actas Urol. Esp. (Engl Ed)"},{"issue":"1","key":"47999_CR32","doi-asserted-by":"publisher","first-page":"17663","DOI":"10.1038\/s41598-022-22577-3","volume":"12","author":"R Vago","year":"2022","unstructured":"Vago, R., Radano, G., Zocco, D. & Zarovni, N. Urine stabilization and normalization strategies favor unbiased analysis of urinary EV content. Sci. Rep. 12 (1), 17663 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"47999_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12894-024-01540-6","volume":"24","author":"J Yu","year":"2024","unstructured":"Yu, J. et al. Unveiling potential: Urinary exosomal mRNAs as non-invasive biomarkers for early prostate cancer diagnosis. BMC Urol. 24(1), 163 (2024).","journal-title":"BMC Urol."},{"key":"47999_CR34","doi-asserted-by":"publisher","first-page":"117525","DOI":"10.1016\/j.cca.2023.117525","volume":"548","author":"AD Singh","year":"2023","unstructured":"Singh, A. D. et al. Exploring urinary extracellular vesicles for organ transplant monitoring: A comprehensive study for detection of allograft dysfunction using immune-specific markers. Clin. Chim. Acta. 548, 117525 (2023).","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"47999_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12967-021-03030-x","volume":"19","author":"Y Feng","year":"2021","unstructured":"Feng, Y. et al. Urinary small extracellular vesicles derived CCL21 mRNA as biomarker linked with pathogenesis for diabetic nephropathy. J. Transl. Med. 19(1), 355 (2021).","journal-title":"J. Transl. Med."},{"key":"47999_CR36","doi-asserted-by":"publisher","first-page":"101715","DOI":"10.1016\/j.trim.2022.101715","volume":"75","author":"AD Singh","year":"2022","unstructured":"Singh, A. D. et al. Identifying stable reference genes in polyethene glycol precipitated urinary extracellular vesicles for RT-qPCR-based gene expression studies in renal graft dysfunction patients. Transpl. Immunol. 75, 101715 (2022).","journal-title":"Transpl. Immunol."},{"issue":"18","key":"47999_CR37","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.18632\/oncotarget.2365","volume":"5","author":"A Neeb","year":"2014","unstructured":"Neeb, A. et al. Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer. Oncotarget 5 (18), 8681\u20138689 (2014).","journal-title":"Oncotarget"},{"issue":"3","key":"47999_CR38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tranon.2018.02.019","volume":"11","author":"L Chunhua","year":"2018","unstructured":"Chunhua, L. et al. Clinical significance of peripheral blood PCA3 gene expression in early diagnosis of prostate cancer. Transl. Oncol. 11(3), 628\u201332 (2018).","journal-title":"Transl. Oncol."},{"issue":"4","key":"47999_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/apm.13382","volume":"132","author":"M Wambach","year":"2024","unstructured":"Wambach, M. et al. Clinical implications of AGR2 in primary prostate cancer: Results from a large-scale study. APMIS 132(4), 256\u201366 (2024).","journal-title":"APMIS"},{"key":"47999_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/1179554920947322","volume":"14","author":"\u00d6 G\u00fclhan","year":"2020","unstructured":"G\u00fclhan, \u00d6. & Mahi, B. The role of AMACR, CD10, TMPRSS2-ERG, and p27 protein expression among different Gleason grades of prostatic adenocarcinoma on needle biopsy. Clin. Med. Insights Oncol. 14, 1179554920947322 (2020).","journal-title":"Clin. Med. Insights Oncol."},{"issue":"3","key":"47999_CR41","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21873\/cdp.10214","volume":"3","author":"T Spinos","year":"2023","unstructured":"Spinos, T. et al. Association between ERG\/PTEN genes and pathologic parameters of prostate cancer with an emphasis on Gleason score: A literature review. Cancer Diagnosis & Prognosis 3(3), 291\u20136 (2023).","journal-title":"Cancer Diagnosis & Prognosis"},{"issue":"10","key":"47999_CR42","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1007\/s11010-025-05318-8","volume":"480","author":"P Salu","year":"2025","unstructured":"Salu, P. & Reindl, K. M. Agr2 in cancer and beyond: Unraveling its role during protein synthesis, ER stress, and as a predictive biomarker. Mol. Cell. Biochem. 480(10), 5205\u201319 (2025).","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"47999_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12894-025-01824-5","volume":"25","author":"MV Ahmadianpour","year":"2025","unstructured":"Ahmadianpour, M. V. & Aleyasin, S. A. CpG dinucleotide methylation of the SPDEF gene as a blood-based epigenetic biomarker for prostate cancer diagnosis. BMC Urol. 25 (1), 145 (2025).","journal-title":"BMC Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47999-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:51:01Z","timestamp":1781221861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47999-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47999"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47999-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18288"}}